Imatinib-induced bone edema: case report and review of literature

J Natl Compr Canc Netw. 2013 Oct 1;11(10):1187-91. doi: 10.6004/jnccn.2013.0140.

Abstract

Imatinib mesylate represents a revolution in the management of patients with metastatic gastrointestinal stromal tumors (GISTs). More recently, postoperative imatinib has been shown to improve both disease-free and overall survivals in patients with a high risk of recurrence. This article presents a well-documented case of a patient with painful and reversible bone edema related to imatinib.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Benzamides / adverse effects*
  • Benzamides / therapeutic use
  • Bone and Bones / drug effects*
  • Bone and Bones / pathology*
  • Edema / chemically induced*
  • Edema / diagnosis
  • Gastrointestinal Stromal Tumors / complications
  • Gastrointestinal Stromal Tumors / drug therapy
  • Humans
  • Imatinib Mesylate
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Piperazines / adverse effects*
  • Piperazines / therapeutic use
  • Protein Kinase Inhibitors / adverse effects*
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrimidines / adverse effects*
  • Pyrimidines / therapeutic use
  • Tomography, X-Ray Computed

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate